ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

Autor:	Kwekkeboom, D. J., Krenning, E. P., Lebtahi, R., Komminoth, P., Kos-Kudla, B., De Herder, W. W., Plockinger, U., Akerstrom, G., Annibale, B., Arnold, R., Bajetta, E., Barkmanova, J., Chen, Y. -J., Costa, F., Couvelard, A., Davar, J., Delle Fave, G., Eriksson, B., Falconi, M., Ferone, D., Gross, D., Grossman, A., Gustafsson, B., Hyrdel, R., Ivan, D., Kaltsas, G., Kianmanesh, R., Kloppel, G., Knigge, U. -P., Lewington, V., Mcnicol, A. M., Mitry, E., Nilsson, O., Oberg, K., O'Connor, J., O'Toole, D., Pape, U. -F., Papotti, M., Pavel, M., Perren, A., Platania, M., Rindi, G., Ruszniewski, P., Salazar, R., Scarpa, A., Scheidhauer, K., Scoazec, J. -Y., Sundin, A., Szpak, W., Taal, B., Vitek, P., Vullierme, M. -P., Wiedenmann, B.
Přispěvatelé:	Radiology & Nuclear Medicine, Internal Medicine
Rok vydání:	2009
Předmět:	Peptide receptor Endocrinology Diabetes and Metabolism Treatment outcome 1 4 7 10 tetraacetic acid Neuroendocrine tumors Endocrinology Receptors comparative study conference paper peptide receptor radionuclide therapy 1 4 7 10 tetraazacyclododecane GEPNET Carcinoids clinical trial yttrium 90 peptide unclassified drug drug dose comparison Somatostatin priority journal neuroendocrine tumor medicine.medical_specialty Receptors Peptide Radiolabeled somatostatin analogues lutetium 177 octreother octreotide[3 tyrosine] pentetreotide in 111 radioisotope somatostatin derivative cancer radiotherapy drug dose escalation human multiple cycle treatment practice guideline treatment duration treatment outcome Cellular and Molecular Neuroscience Internal medicine medicine Humans Radioisotopes Radiotherapy Endocrine and Autonomic Systems business.industry Guideline Neuroendocrine Tumors medicine.disease Clinical trial Cancer Radiotherapy Radionuclide therapy business
Zdroj:	Neuroendocrinology, 90(2), 220-226. Karger
ISSN:	0028-3835
Popis:	The purpose of this guideline is to assist physicians caring for patients with neuroendocrine tumors in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT), and in defining the minimum requirements for PRRT. This guideline also makes recommendations on what minimal patient, tumor, and treatment outcome characteristics should be reported for PRRT in order to make comparisons between studies possible. It is not this guideline's aim to give specific recommendations on the use of specific radiolabeled somatostatin analogs for PRRT because different analogs are being used, and their availability depends on national law and local permissions. Copyright (C) 2009 S. Karger AG, Basel
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fc48e899b3ac110e39dc95a1f0a2453 https://pure.eur.nl/en/publications/359c8de7-2feb-41db-9b1c-6841585f2a4f Zobrazit plný text záznamu